Crescita Financial Statements From 2010 to 2025

CTX Stock  CAD 0.46  0.02  4.17%   
Crescita Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Crescita Therapeutics' valuation are provided below:
Gross Profit
10.5 M
Profit Margin
(0.07)
Market Capitalization
8.7 M
Enterprise Value Revenue
0.0701
Revenue
20.3 M
We have found one hundred twenty available fundamental signals for Crescita Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Crescita Therapeutics' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 14th of August 2025, Market Cap is likely to grow to about 14.4 M, while Enterprise Value is likely to drop about 2.6 M.

Crescita Therapeutics Total Revenue

14.92 Million

Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 61.8 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.54, Dividend Yield of 0.0 or PTB Ratio of 0.74. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.

Crescita Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets25.3 M21.8 M17.8 M
Slightly volatile
Other Current Liabilities47.5 K50 K928.3 K
Slightly volatile
Total Current Liabilities5.9 M5.5 MM
Slightly volatile
Other Liabilities203.6 K110.7 K217.5 K
Pretty Stable
Property Plant And Equipment Net1.4 M2.4 M951.7 K
Slightly volatile
Accounts Payable4.5 MM3.5 M
Slightly volatile
Cash8.8 M9.3 M6.2 M
Slightly volatile
Non Current Assets Total8.8 M6.5 M6.1 M
Slightly volatile
Cash And Short Term Investments9.7 M9.3 M6.8 M
Slightly volatile
Net Receivables2.8 M1.6 M2.1 M
Slightly volatile
Common Stock Shares Outstanding19.3 M19.1 M15.9 M
Slightly volatile
Short Term Investments2.6 K2.7 K559.8 K
Very volatile
Liabilities And Stockholders Equity25.3 M21.8 M17.8 M
Slightly volatile
Non Current Liabilities Total410.4 K432 K1.4 M
Very volatile
Inventory3.7 M4.1 M2.7 M
Slightly volatile
Other Current Assets2.9 KK201.2 K
Slightly volatile
Total Liabilities5.9 M5.9 M6.4 M
Pretty Stable
Property Plant And Equipment Gross5.2 MM1.8 M
Slightly volatile
Total Current Assets16.6 M15.3 M11.8 M
Slightly volatile
Accumulated Other Comprehensive Income1.2 M1.3 M1.1 M
Pretty Stable
Property Plant Equipment1.4 M2.4 M951.7 K
Slightly volatile
Short and Long Term Debt Total1.1 M1.1 M1.7 M
Pretty Stable
Long Term Debt Total346.8 K365 K1.3 M
Very volatile
Capital Surpluse7.7 M7.4 M2.3 M
Slightly volatile
Short and Long Term Debt1.2 M1.1 M935.4 K
Slightly volatile
Non Current Liabilities Other63.6 K67 K535.5 K
Slightly volatile
Cash And Equivalents10.7 M9.3 M9.8 M
Very volatile
Intangible Assets1.6 M1.7 MM
Slightly volatile
Net Invested Capital16.2 M15.8 M18.8 M
Pretty Stable
Net Working Capital13.1 M9.8 M9.5 M
Slightly volatile
Common Stock Total Equity46.9 M52.4 M57.7 M
Slightly volatile
Capital Stock45.4 M52.7 M57.3 M
Slightly volatile
Capital Lease Obligations1.2 M834 K851.2 K
Slightly volatile
Long Term Investments269.8 K311 K333.6 K
Slightly volatile

Crescita Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.7 M918.8 K
Slightly volatile
Interest Expense61.8 K65 K188 K
Pretty Stable
Selling General Administrative10.5 M10.8 M8.8 M
Slightly volatile
Total Revenue14.9 M19.6 M10.5 M
Slightly volatile
Gross Profit9.1 M9.6 M6.4 M
Slightly volatile
Other Operating Expenses19.2 M22.4 M17.1 M
Slightly volatile
Research Development613.7 K646 K3.5 M
Slightly volatile
Cost Of Revenue5.8 M10 M4.1 M
Slightly volatile
Total Operating Expenses15 M22.8 M13.8 M
Very volatile
Interest Income239.5 K343 K160.1 K
Slightly volatile
Reconciled Depreciation1.5 M1.4 M1.3 M
Slightly volatile

Crescita Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation169.7 K181 K217.7 K
Slightly volatile
Begin Period Cash Flow7.9 M9.4 M5.6 M
Slightly volatile
Depreciation1.2 M1.4 M900.3 K
Slightly volatile
Capital Expenditures1.2 M1.2 M251.5 K
Slightly volatile
End Period Cash Flow8.8 M9.3 M6.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.540.57097.6196
Slightly volatile
Days Sales Outstanding30.3931.9888149
Slightly volatile
Stock Based Compensation To Revenue0.00880.00920.1113
Slightly volatile
Capex To Depreciation0.910.86750.2679
Slightly volatile
EV To Sales0.130.13997.1545
Slightly volatile
Inventory Turnover2.582.46161.3388
Slightly volatile
Days Of Inventory On Hand141148341
Slightly volatile
Payables Turnover2.11.9960.9838
Slightly volatile
Sales General And Administrative To Revenue0.520.55212.8601
Slightly volatile
Research And Ddevelopement To Revenue0.03130.0333.5394
Slightly volatile
Capex To Revenue0.06350.06050.0321
Slightly volatile
Cash Per Share0.410.48120.3846
Slightly volatile
Days Payables Outstanding174183945
Slightly volatile
Intangibles To Total Assets0.07570.07970.2855
Slightly volatile
Current Ratio2.162.7752.0991
Slightly volatile
Receivables Turnover11.9811.41034.9498
Slightly volatile
Debt To Equity0.05010.05270.2006
Slightly volatile
Capex Per Share0.06460.06150.0139
Slightly volatile
Revenue Per Share0.571.0160.5439
Slightly volatile
Interest Debt Per Share0.04430.04660.1169
Very volatile
Debt To Assets0.03640.03830.129
Slightly volatile
Graham Number1.171.121.3414
Slightly volatile
Operating Cycle171180490
Slightly volatile
Days Of Payables Outstanding174183945
Slightly volatile
Long Term Debt To Capitalization0.04620.04860.1344
Slightly volatile
Total Debt To Capitalization0.04750.05010.1592
Slightly volatile
Debt Equity Ratio0.05010.05270.2006
Slightly volatile
Quick Ratio1.662.04041.6132
Slightly volatile
Net Income Per E B T1.450.99491.2129
Pretty Stable
Cash Ratio1.171.68141.1104
Slightly volatile
Days Of Inventory Outstanding141148341
Slightly volatile
Days Of Sales Outstanding30.3931.9888149
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.10.56511.0084
Very volatile
Fixed Asset Turnover13.788.080911.7795
Pretty Stable
Debt Ratio0.03640.03830.129
Slightly volatile
Price Sales Ratio0.540.57097.6196
Slightly volatile
Asset Turnover0.50.89920.588
Slightly volatile
Gross Profit Margin0.460.49070.5933
Slightly volatile

Crescita Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14.4 M11.2 M13.8 M
Slightly volatile
Enterprise Value2.6 M2.7 MM
Slightly volatile

Crescita Fundamental Market Drivers

Cash And Short Term Investments9.3 M

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5 M-5.3 M
Total Revenue19.6 M14.9 M
Cost Of Revenue10 M5.8 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.55  0.52 
Research And Ddevelopement To Revenue 0.03  0.03 
Capex To Revenue 0.06  0.06 
Revenue Per Share 1.02  0.57 
Ebit Per Revenue(0.16)(0.17)

Pair Trading with Crescita Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crescita Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crescita Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Crescita Stock

  0.58SPD Silver Predator CorpPairCorr
  0.56TIN Tincorp Metals Earnings Call This WeekPairCorr
  0.51LI American Lithium CorpPairCorr
  0.35SCD Scandium CanadaPairCorr
The ability to find closely correlated positions to Crescita Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crescita Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crescita Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crescita Therapeutics to buy it.
The correlation of Crescita Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crescita Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crescita Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crescita Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.